Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Effects of Evolocumab and Atorvastatin in Healthy Men
NCT06140095Phase 1Not yet recruiting
- Sponsor
- Region Stockholm
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of evolocumab in hypercholesterolemia, sponsored by Region Stockholm. Primary endpoints: Cholesterol metabolism effect at 32 hours and Bile acid metabolism effect at 32 hours. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06140095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140095.